Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
186.13
-0.32 (-0.17%)
Oct 24, 2025, 4:00 PM EDT - Market closed
Krystal Biotech Revenue
Krystal Biotech had revenue of $96.04M in the quarter ending June 30, 2025, with 36.65% growth. This brings the company's revenue in the last twelve months to $359.21M, up 116.08% year-over-year. In the year 2024, Krystal Biotech had annual revenue of $290.52M with 473.02% growth.
Revenue (ttm)
$359.21M
Revenue Growth
+116.08%
P/S Ratio
14.92
Revenue / Employee
$1,306,200
Employees
275
Market Cap
5.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
KRYS News
- 5 weeks ago - FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin - Benzinga
- 5 weeks ago - Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label - GlobeNewsWire
- 2 months ago - Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update - Seeking Alpha
- 2 months ago - Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 3 months ago - Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté - GlobeNewsWire
- 3 months ago - Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - GlobeNewsWire